by 
Causes and Symptoms of Muscular Dystrophy
Muscular dystrophy refers to a group of inherited genetic disorders that weaken the muscles over time. There are several different types of muscular dystrophy, each caused by mutations or defects in specific genes. The most common gene mutations that cause muscular dystrophy affect proteins needed to build and maintain healthy muscles, such as dystrophin. Symptoms can vary depending on the particular type but often include progressive muscle weakness and loss of muscle mass. Some common signs and symptoms of muscular dystrophy include difficulty walking, climbing stairs, rising from chairs, difficulty brushing teeth or doing day-to-day activities with the hands and difficulty swallowing.
Current Treatment Approaches
While there is currently no cure, several muscular dystrophy treatments can help manage symptoms and potentially slow progression. Physical therapy plays an important role by helping to maintain mobility and muscle strength for as long as possible. Assistive devices like braces, walkers and wheelchairs can help with mobility challenges. Corticosteroids are sometimes used to try and slow muscle degeneration, though their long-term effectiveness is uncertain. Surgery may be used to correct orthopedic issues like scoliosis. Occupational therapy can teach skills to help daily living. Genetic counseling can help educate families about risks and family planning options. Careful symptom management through a multidisciplinary team approach is important.
Gene Therapy Clinical Trials
One of the most promising areas of research is gene therapy. This approach aims to supplement or fix the defective gene that is causing muscular dystrophy. Several gene therapy clinical trials for different types of muscular dystrophy are currently underway. One example is a phase 1/2a clinical trial testing a gene therapy approach for Duchenne muscular dystrophy (DMD). DMD is caused by mutations in the dystrophin gene. In this trial, researchers use an AAV vector to deliver a microdystrophin gene selectively to muscle tissue. Early results have found the treatment to be safe and well-tolerated in patients, with some signs it may help stabilize muscle function. Larger late-stage clinical trials will be needed but these initial gene therapy studies offer hope.
Promising Antisense Oligonucleotide Therapies
Another new and promising avenue being explored is the use of antisense oligonucleotides (ASOs). ASOs are short strands of modified DNA or RNA that can alter splicing of pre-mRNA. For certain muscular dystrophies caused by pre-mRNA splicing defects, ASOs may be able to modify splicing in a way that restores the function of the mutant gene. For example, in DMD where out-of-frame deletions disrupt the dystrophin gene, ASOs can promote in-frame exon skipping to potentially turn the non-function mutation into a milder Becker muscular dystrophy mutation. Several DMD ASO therapies have shown ability in clinical trials to successfully promote exon skipping, restore dystrophin production and potentially stabilize muscle function. The ASO eteplirsen was approved by the FDA in 2016 for DMD treatment. Further research is exploring the use of ASOs for other types of muscular dystrophy as well.
Advances in Cell-Based Therapies
Another category of cutting-edge treatments involves cell-based therapies. One strategy involves transplanting muscle stem cells, also called satellite cells, into muscles affected by muscular dystrophy. In early clinical trials for DMD, researchers have transplanted autologous CD34+ cells that were either unmodified or had been engineered to overexpress utrophin. This protein can help compensate for lost dystrophin. While safety has been shown, efficacy requires more investigation. Researchers are also exploring stem cell-based approaches like using induced pluripotent stem cells (iPSCs) derived from a patient’s own skin or blood cells. iPSCs can potentially be guided to differentiate into healthy muscle cells that could replace damaged muscle tissue. Challenges include efficiently transplanting enough cells to achieve therapeutic benefits. Overall, stem cell therapies hold promise but need more research before being ready for widespread clinical use.
Outlook for Continued Treatment Progress
Research into new and better muscular dystrophy treatments is very active. With myriad clinical trials underway evaluating gene, cell and drug-based therapies, physicians are optimistic that in the next 5-10 years several new and effective treatment options will become available for many forms of this currently incurable condition. A multimodal treatment approach combining emerging therapies with standard supportive care will likely provide the best outcomes by targeting the disease from different angles. With new treatments on the horizon and a dedicated worldwide research effort, patients with muscular dystrophy can hope to see ongoing improvements in managing both their symptoms and the progression of their condition. Continued research progress gives hope that even a cure may one day become a reality for some types of muscular dystrophy.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
